Should Patients with Obesity and Hypertension be Treated Differently from Those Who Are Not Obese?

Therapeutic Trials (B Pitt, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Therapeutic Trials


Obesity and hypertension frequently coexist. Measuring blood pressure (BP) accurately in obese patients is challenging and may require strategies that are less accurate, such as forearm cuffing or use of wrist cuffs. Pathophysiologic mechanisms of hypertension may differ between obese and non-obese individuals, which may result in differing effects of common BP-lowering medications. However, to date, there is insufficient trial data to recommend a different approach to medication selection based on body mass index. Additionally, the goal BP is generally not different between obese and non-obese patients. Weight loss should be emphasized for obese patients with hypertension, and interventions in addition to diet and exercise may include weight loss medications and bariatric surgery. Recognition and treatment of obstructive sleep apnea is also important.


Hypertension Obesity Body mass Index Blood pressure measurement Ambulatory blood pressure monitoring Home blood pressure monitoring Obstructive sleep apnea Sympathetic nervous system Renin angiotensin system Adiposity Arm circumference Blood pressure cuff size Obesity paradox Weight loss Blood pressure goals ACCOMPLISH blood pressure study Polysomnogram 



body mass index


blood pressure


cardiovascular disease


  1. 1.
    Centers for Disease Control. Healthy weight, overweight, and obesity among U.S. adults. National Health and Nutrition Examination Survey. Available at: Accessed Nov 7, 2013
  2. 2.
    Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011-2012. NCHS Data Brief. 2013;131:1–8.PubMedGoogle Scholar
  3. 3.
    Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Quesenberry Jr CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med. 1998;158:466–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G. Body mass index and future healthcare costs: a retrospective cohort study. Obes Res. 2001;9:210–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood). 2003 Jan-Jun;Suppl Web Exclusives:W3–219–26.Google Scholar
  7. 7.
    Landsberg L, Aronne LJ, Beilin L, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment. A position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15:14–33. Reviews the pathophysiology of obesity-related hypertension and provides recommendations for management, including medical treatments for obesity.CrossRefGoogle Scholar
  8. 8.
    Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010;23(11):1170–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord. 2002;26(1):48–57.PubMedCrossRefGoogle Scholar
  10. 10.
    Graves JW, Bailey KR, Sheps SG. The changing distribution of arm circumferences in NHANES III and NHANES 2000 and its impact on the utility of the 'standard adult' blood pressure cuff. Blood Press Monit. 2003;8(6):223–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Ostchega Y, Huges JP, Zhang G, et al. Mean mid-arm circumference and blood pressure cuff sizes for US adults: National Health and Nutrition Examination Survey, 1999-2010. Blood Press Monit. 2013;18(3):138–43. This report from the NHANES observational study suggests that 42.9% of men and 25.3% of women require a large cuff for accurate BP measurement. PubMedCrossRefGoogle Scholar
  12. 12.
    Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood Pressure Measurement in Humans: A Statement for Professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Palatini P, Parati G. Blood pressure measurement in very obese patients: A challenging problem. J Hypertens. 2011;29:425–9. This seminal article remains the most comprehensive summary of recommendations for BP measurement. Office, home, and ambulatory BP measurement are all covered, with emphasis on practical recommendations. PubMedCrossRefGoogle Scholar
  14. 14.
    Bonso E, Saladini F, Zanier A, et al. Accuracy of a single rigid conical cuff with standard size bladder coupled to an automated oscillometric device over a wide range of arm circumferences. Hypertens Res. 2010;33:1186–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Mourad JJ, Lopez-Sublet M, Aoun-Bahous S, et al. Impact of miscuffing during home blood pressure measurement on the prevalence of masked hypertension. Am J Hypertens. 2013;26(10):1205–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Maxwell GF, Prujit JF, Amtzenius AC. Comparison of conical cuff and the standard rectangular cuffs. Int J Epidemiol. 1985;14:468–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;25:343.Google Scholar
  19. 19.
    Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925–38. This article is one of the more recent guidelines for hypertension management. CrossRefGoogle Scholar
  20. 20.
    Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm Jr RH, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780–800.PubMedCrossRefGoogle Scholar
  21. 21.
    James PA, Oparil S, Carter BL, et al. Evidence Based Guidelines for the Management of High Blood Pressure in Adults: Report from the panel members appointed to the eighth joint national committee (JNC8). JAMA. 2013. doi:10.1001/jama.2013.284427.Google Scholar
  22. 22.
    Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120:863–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Wassertheil-Smoller S, Fann C, Allman RM, et al. Relation of low body mass to death and stroke in systolic hypertension in the elderly program. Arch Intern Med. 2000;160:494–500.PubMedCrossRefGoogle Scholar
  25. 25.
    Weber MA, Jamerson K, Bakris G, et al. Effects of body size and hypertension treatment on cardiovascular event rates: subanalysis of the ACCOMPLISH randomized controlled trial. Lancet. 2013. This pre-specified analysis of the results of the ACCOMPLISH study suggests that the combination of an ACE inhibitor + a calcium channel blocker offers equal reduction in CV events in lean and obese patients, but that the combination of an ACE inhibitor + diuretic offers better reduction of CV events in overweight as opposed to lean individuals.Google Scholar
  26. 26.
    Jamerson K, Weber MA, Bakris G, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Eng J Med. 2008;359:2417–28.CrossRefGoogle Scholar
  27. 27.
    Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43(3):518–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Tirosh A, Garg R, Adler GK. Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome. Curr Hypertens Rep. 2010;12:252–7.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertens. 2010;55:147–52.CrossRefGoogle Scholar
  30. 30.
    Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertens. 2007;49:839–45.CrossRefGoogle Scholar
  31. 31.
    ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. JAMA. 2002;288(23):2981–97.CrossRefGoogle Scholar
  32. 32.
    Vgontzas AN, Tan TL, Bixler EO, Martin LF, Shubert D, Kales A. Sleep apnea and sleep disruption in obese patients. Arch Intern Med. 1994;154:1705–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg. 2003;13:676–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of obstructive sleep apnea without polysomnography. Ann Intern Med. 2007;146:157–66.PubMedCrossRefGoogle Scholar
  36. 36.
    Skomro RP, Gjevre J, Reid J, et al. Outcomes of home-based diagnosis and treatment of obstructive sleep apnea. Chest. 2010;138(2):257–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Yalamanchali S, Farajian V, Hamilton C, Pott TR, Samuelson CG, Friedman M. Diagnosis of obstructive sleep apnea by peripheral arterial tonometry: meta-analysis. JAMA Otolaryngol Head Neck Surg. 2013. doi:10.1001/jamaoto.2013.5338.PubMedGoogle Scholar
  38. 38.
    Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003;107(1):68–73.PubMedCrossRefGoogle Scholar
  39. 39.
    Alajmi M, Mulgrew AT, Fox J, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. Lung. 2007;185(2):67–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Somers VK, White DP, Ain R, et al. Sleep apnea and cardiovascular disease: An American heart association/American college of cardiology foundation scientific statement from the American heart association council for high blood pressure research professional education committee. J Am Coll Cardiol. 2008;5d2(8):686–717. This scientific statement suggests that the presence of OSA is closely associated with hypertension and other CV disease, but that the effect of CPAP on BP reduction in hypertensive patients with OSA is modest – on the order of about 3 mmHg systolic. CrossRefGoogle Scholar
  41. 41.
    Martinez-Garcia MA, Capote F, Campos-Rodriguez F, et al. Effect of CPAP on blood pressure in patient with obstructive sleep apnea and resistant hypertension: The HIPARCO Randomized Clinical Trial. JAMA. 2013;310(22):2407–15.PubMedGoogle Scholar
  42. 42.
    Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized trial. JAMA. 2012;307(20):2161–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84.PubMedCrossRefGoogle Scholar
  44. 44.
    Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20:2257–67.PubMedCrossRefGoogle Scholar
  45. 45.
    Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev. 2013;3:CD007654.PubMedGoogle Scholar
  46. 46.
    Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMedCrossRefGoogle Scholar
  47. 47.
    Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.PubMedCrossRefGoogle Scholar
  48. 48.
    Ricci C, Gaeta M, Rausa E, Macchitella Y, Bonavina L. Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6,587 patients. Obes Surg. 2013.Google Scholar
  49. 49.
    Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013. doi:10.1001/jama.2013.280928. This recently published study highlights the weight loss and metabolic benefits at three years of weight loss achieved through bariatric surgery. Google Scholar
  50. 50.
    Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.CrossRefGoogle Scholar
  51. 51.
    Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Nevada School of MedicineRenoUSA
  2. 2.Renown Institute for Heart & Vascular Health, Renown Regional Medical CenterRenoUSA
  3. 3.Department of Family MedicineUniversity of North Carolina School of MedicineChapel HillUSA
  4. 4.Hypertension Research ProgramUniversity of North CarolinaChapel HillUSA

Personalised recommendations